Anti-inflammatory effects of GLP1-RA drugs
The Journal of Clinical Endocrinology & Metabolism · 13.08.2026 · 111 (9) · e2076-e2085
DOI: 10.1210/clinem/dgag218 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 01.06.2026. Verfasst von Luis Quintana und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Glucagon-Like Peptide-1 Receptor Agonists, Inflammation, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation, Emmy Noether Research Group.
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are established treatment options for type 2 diabetes and obesity. This class of medications has redefined care by lowering glucose, reducing body weight, and improving cardiovascular outcomes. Beyond metabolic benefits, accumulating evidence indicates that GLP-1RA exert direct anti-inflammatory effects across multiple organ systems. Chronic inflammation is a driving force behind many prevalent diseases, including diabetes, cardiovascular disease, neurodegenerative disorders, and inflammatory bowel disease. This review summarizes the current evidence of the anti-inflammatory effects of GLP-1RA, highlighting data from preclinical models and clinical trials across different diseases. By targeting both metabolic and inflammatory pathways, GLP-1RA may offer dual cardiometabolic and immunomodulatory protection, positioning these agents as promising candidates for broader therapeutic applications. However, several key questions remain regarding causality, the precise molecular mechanisms involved, and the extent to which these anti-inflammatory effects can be translated into effective therapies for nonmetabolic inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany.
ORCID-Profile: Berkan Kurt, Florian Kahles
Förderung
- Deutsche Forschungsgemeinschaft
- German Research Foundation
- Emmy Noether Research Group
- European Research Area Network on Cardiovascular Diseases
- BMBF
- European Foundation for the Study of Diabetes (EFSD)
- Novo Nordisk Foundation
- Interdisciplinary Centre for Clinical Research
Zitieren
APA
Quintana, L., Tabaza, N., Kurt, B., & Kahles, F. (2026). Anti-inflammatory effects of GLP1-RA drugs. The Journal of Clinical Endocrinology & Metabolism, 111(9), e2076-e2085. https://doi.org/10.1210/clinem/dgag218
Vancouver
Quintana L, Tabaza N, Kurt B, Kahles F. Anti-inflammatory effects of GLP1-RA drugs. The Journal of Clinical Endocrinology & Metabolism. 2026;111(9):e2076-e2085. doi:10.1210/clinem/dgag218
BibTeX
@article{Quintana2026,
author = {Quintana, Luis and Tabaza, Nadim and Kurt, Berkan and Kahles, Florian},
title = {Anti-inflammatory effects of GLP1-RA drugs},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {9},
pages = {e2076--e2085},
doi = {10.1210/clinem/dgag218}
}
EUVIMED